UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE
SECURITIES EXCHANGE ACT OF 1934
|
For the month of September, 2018
|
|
|
|
|
|
|
|
Commission File Number 001-35463
|
|
Taro Pharmaceutical Industries Ltd.
(Translation of registrant’s name into English)
14 Hakitor Street, Haifa Bay 2624761, Israel
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ☐ No ☒
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_____.
 |
Taro Pharmaceutical Industries Ltd.
c/o Taro Pharmaceuticals U.S.A., Inc.
Three Skyline Drive
Hawthorne, New York 10532
(NYSE: TARO)
|
FOR IMMEDIATE RELEASE
|
CONTACTS:
|
|
|
|
Mariano A. Balaguer
|
William J. Coote
|
|
|
VP, CFO
|
AVP, Business Finance, Treasurer and Investor Relations
|
|
|
(914) 345-9001
|
(914) 345-9001
|
|
|
Mariano.Balaguer@taro.com
|
William.Coote@taro.com
|
|
TARO TERMINATES AGREEMENT WITH NOVABIOTICS
License agreement for anti-fungal peptide treatment, Novexatin®
Hawthorne, NY, September 28, 2018 - Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) announced today that it has terminated the license agreement with NovaBiotics for the onychomycosis drug, Novexatin®.
As previously disclosed in May 2018, the Novexatin® clinical study did not meet the main goal of a Phase IIb study under current guidelines of the FDA and did not show superiority over the placebo. Upon further analysis and evaluation, the Company has decided to terminate its agreement with NovaBiotics.
************************
About Taro
Taro Pharmaceutical Industries Ltd. is a multinational, science-based pharmaceutical company, dedicated to meeting the needs of its customers through the discovery, development, manufacturing and marketing of the highest quality healthcare products. For further information on Taro Pharmaceutical Industries Ltd., please visit the Company’s website at www.taro.com.
About NovaBiotics
NovaBiotics Ltd is a clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Date: September 28, 2018
|
|
|
|
|
|
|
|
TARO PHARMACEUTICAL INDUSTRIES LTD.
|
|
|
|
|
|
|
|
By:
|
/s/ Uday Baldota
|
|
|
|
Name: Uday Baldota
|
|
|
|
Title: Chief Executive Officer and Director
|
|